Ginette Serrero
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$5.5MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $5.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 23, 2022 | NIH | SBIR Phase II A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | $71K | — |
| Mar 24, 2022 | NIH | SBIR Phase II Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | $827K | — |
| Aug 30, 2021 | NIH | SBIR Phase II A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | $142K | — |
| Sep 1, 2020 | NIH | SBIR Phase II Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | $1.1M | — |
| Aug 31, 2018 | NIH | SBIR Phase II Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | $159K | — |
| Aug 29, 2018 | NIH | SBIR Phase II Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | $833K | — |
| Aug 23, 2018 | NIH | SBIR Phase II A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | $1.1M | — |
| Sep 15, 2017 | NIH | SBIR Phase II Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | $1.2M | — |
| Mar 2, 2017 | NIH | SBIR Phase I A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | $153K | — |
Peer ranks
Federal funding#56
Awards as PI#67
Patents#27
Companies
No tracked company linked yet.
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.